{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:03:30Z","timestamp":1790363010190,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T00:00:00Z","timestamp":1421712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s40265-015-0351-8","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T08:50:59Z","timestamp":1421657459000},"page":"297-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis"],"prefix":"10.1007","volume":"75","author":[{"given":"Greg L.","family":"Plosker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,20]]},"reference":[{"issue":"9 Suppl 22","key":"351_CR1","first-page":"1","volume":"9","author":"SA Gregory","year":"2011","unstructured":"Gregory SA, Mesa RA, Hoffman R, et al. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011;9(9 Suppl 22):1\u201316.","journal-title":"Clin Adv Hematol Oncol."},{"key":"351_CR2","first-page":"89","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, et al. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89\u2013101.","journal-title":"Int J Gen Med."},{"issue":"1","key":"351_CR3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14\u201322.","journal-title":"Leukemia."},{"issue":"3","key":"351_CR4","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","volume":"55","author":"J Mehta","year":"2014","unstructured":"Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595\u2013600.","journal-title":"Leuk Lymphoma."},{"issue":"13","key":"351_CR5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood."},{"issue":"1","key":"351_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25\u201333.","journal-title":"Mayo Clin Proc."},{"issue":"12","key":"351_CR7","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1182\/blood-2014-01-551267","volume":"123","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S. Changing myelofibrosis\u2019s natural course at last. Blood. 2014;123(12):1776\u20137.","journal-title":"Blood."},{"issue":"26","key":"351_CR8","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2174\/092986712803251511","volume":"19","author":"J Mascarenhas","year":"2012","unstructured":"Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26):4399\u2013413.","journal-title":"Curr Med Chem."},{"issue":"9","key":"351_CR9","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.2174\/187152012803529727","volume":"12","author":"FP Santos","year":"2012","unstructured":"Santos FP, Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 2012;12(9):1098\u2013109.","journal-title":"Anticancer Agents Med Chem."},{"issue":"3","key":"351_CR10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ehm.10.28","volume":"3","author":"ST Oh","year":"2010","unstructured":"Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010;3(3):323\u201337.","journal-title":"Expert Rev Hematol."},{"issue":"5","key":"351_CR11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573\u201382.","journal-title":"J Clin Oncol."},{"issue":"25","key":"351_CR12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med."},{"issue":"16","key":"351_CR13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2165\/11209340-000000000-00000","volume":"72","author":"LPH Yang","year":"2012","unstructured":"Yang LPH, Keating GM. Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012;72(16):2117\u201327.","journal-title":"Drugs."},{"issue":"15","key":"351_CR14","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood."},{"key":"351_CR15","unstructured":"Jakafi (ruxolitinib) tablets for oral use: US prescribing information. 2014. http:\/\/www.incyte.com\/sites\/default\/files\/Jakafi_PI_0.pdf . Accessed 24 Dec 2014."},{"issue":"12","key":"351_CR16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med."},{"key":"351_CR17","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807 [plus supplementary appendix].","DOI":"10.1056\/NEJMoa1110557"},{"key":"351_CR18","doi-asserted-by":"crossref","unstructured":"Vannucchi A, Kiladjian JJ, Gisslinger H, et al. Reductions in Jak2v617f allele burden with ruxolitinib treatment in Comfort-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT) [abstract no. 0373]. In: 17th Congress of the European Haematology Association. 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.6514"},{"issue":"2","key":"351_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127\u201340.","journal-title":"Nat Rev Drug Discov."},{"key":"351_CR20","unstructured":"European Medicines Agency. Jakavi tablets: summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002464\/WC500133223.pdf . Accessed 30 Sep 2014."},{"issue":"12","key":"351_CR21","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","volume":"51","author":"JG Shi","year":"2011","unstructured":"Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51(12):1644\u201354.","journal-title":"J Clin Pharmacol."},{"issue":"11","key":"351_CR22","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","volume":"38","author":"AD Shilling","year":"2010","unstructured":"Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans. Drug Metab Dispos. 2010;38(11):2023\u201331.","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"351_CR23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jcph.102","volume":"53","author":"X Chen","year":"2013","unstructured":"Chen X, Williams WV, Sandor V, et al. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol. 2013;53(7):721\u201330.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"351_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12185-013-1280-5","volume":"97","author":"Y Ogama","year":"2013","unstructured":"Ogama Y, Mineyama T, Yamamoto A, et al. A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. Int J Hematol. 2013;97(3):351\u20139.","journal-title":"Int J Hematol."},{"issue":"6","key":"351_CR25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012;52(6):809\u201318.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"351_CR26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202\u20139.","journal-title":"Blood."},{"key":"351_CR27","doi-asserted-by":"crossref","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy [abstract no. 4055]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.4055.4055"},{"issue":"12","key":"351_CR28","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865\u201371.","journal-title":"Haematologica."},{"key":"351_CR29","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I [abstract no. 396]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.396.396"},{"issue":"4","key":"351_CR30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508\u201316.","journal-title":"Br J Haematol."},{"issue":"10","key":"351_CR31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285\u201392.","journal-title":"J Clin Oncol."},{"key":"351_CR32","doi-asserted-by":"crossref","unstructured":"Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I [abstract no. 1733]. Blood. 2012;120(21).","DOI":"10.1182\/blood.V120.21.1733.1733"},{"key":"351_CR33","doi-asserted-by":"crossref","unstructured":"Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6(1).","DOI":"10.1186\/1756-8722-6-79"},{"key":"351_CR34","doi-asserted-by":"crossref","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398 [plus supplementary appendix].","DOI":"10.1056\/NEJMoa1110556"},{"issue":"25","key":"351_CR35","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047\u201353.","journal-title":"Blood."},{"issue":"12","key":"351_CR36","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833\u20135.","journal-title":"Blood."},{"issue":"15","key":"351_CR37","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","volume":"365","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455\u20137.","journal-title":"N Engl J Med."},{"issue":"14","key":"351_CR38","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","volume":"123","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123(14):2157\u201360.","journal-title":"Blood."},{"issue":"2","key":"351_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12375","volume":"162","author":"CN Harrison","year":"2013","unstructured":"Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162(2):229\u201339.","journal-title":"Br J Haematol."},{"key":"351_CR40","unstructured":"Harrison C, Kiladjian JJ, Gisslinger H, et al. Multivariate analysis of the association of cytokine levels and reductions in spleen size in COMFORT-II, a phase 3 study comparing ruxolitinib to best available therapy (BAT) [abstract no. P269]. In: 18th Congress of the European Haematology Association. 2013."},{"key":"351_CR41","doi-asserted-by":"crossref","unstructured":"Harrison C, Kiladjian JJ, Gisslinger H, et al. Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase 3 study comparing ruxolitinib to best available therapy (BAT) [abstract no. 0379]. In: 17th Congress of the European Haematology Association. 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.6625"},{"key":"351_CR42","doi-asserted-by":"crossref","unstructured":"Squires M, Harrison CN, Barosi G, et al. The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT) [abstract no. 4070]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.4070.4070"},{"key":"351_CR43","unstructured":"Vannucchi AM, Hagop K, Kiladjian JJ, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis [abstract no. 2820]. Blood. 2013;122(21)."},{"key":"351_CR44","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian HM, Ning J, et al. Prognostic factors for outcome in patients (pts) with myelofibrosis (MF) treated with ruxolitinib (Rux) [abstract no. 4050]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.4050.4050"},{"issue":"2","key":"351_CR45","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2013.087650","volume":"99","author":"RA Mesa","year":"2014","unstructured":"Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014;99(2):292\u20138.","journal-title":"Haematologica."},{"key":"351_CR46","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kiladjian JJ, Mesa RA, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials [abstract no. 2847]. Blood. 2012;120(21).","DOI":"10.1182\/blood.V120.21.2847.2847"},{"key":"351_CR47","doi-asserted-by":"crossref","unstructured":"Jung CW, Shih LY, Xiao Z, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma. 2014:1\u201322.","DOI":"10.3109\/10428194.2014.969260"},{"key":"351_CR48","unstructured":"Oritani K, Okamoto S, Tauchi T, et al. Efficacy and safety of ruxolitinib in Japanese patients with myelofibrosis (MF) [abstract no. OS-2-49]. In: 76th Annual Meeting of the Japanese Society of Hematology. 2014."},{"key":"351_CR49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6:81.","journal-title":"J Hematol Oncol."},{"key":"351_CR50","doi-asserted-by":"crossref","unstructured":"Andreoli A, Rey J, Dauriac C, et al. Ruxolitinib therapy in myelofibrosis: Analysis of 241 patients treated in compassionate use (French \u201cATU\u201d program) by the French intergroup of myeloproliferative neoplasms (FIM) [abstract no. 2841]. Blood. 2012;120(21).","DOI":"10.1182\/blood.V120.21.2841.2841"},{"key":"351_CR51","doi-asserted-by":"crossref","unstructured":"Alzate MA, Osorio MJM, Barreyro P, et al. Ruxolitinib in myelofibrosis (MF) patients through compassionate use program (CUP). Argentinian experience [abstract no. 5247]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.5247.5247"},{"key":"351_CR52","doi-asserted-by":"crossref","unstructured":"Tabarroki A, Lindner D, Visconte V, et al. Modified dose escalation of ruxolitinib: a feasible therapeutic approach in the management of myelofibrosis [abstract no. 1586]. Blood. 2013;122(21).","DOI":"10.1182\/blood.V122.21.1586.1586"},{"key":"351_CR53","unstructured":"Harrison CN, Clark RE, Chacko J, et al. Response to ruxolitinib in patients with intermediate-1, intermediate-2 and high-risk myelofibrosis: interim results of the UK Robust Trial [abstract no. 2826]. Blood. 2013;122(21)."},{"issue":"7","key":"351_CR54","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1517\/14740338.2014.916273","volume":"13","author":"S Galli","year":"2014","unstructured":"Galli S, McLornan D, Harrison C. Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opin Drug Saf. 2014;13(7):967\u201376.","journal-title":"Expert Opin Drug Saf."},{"key":"351_CR55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OTT.S53348","volume":"7","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13\u201321.","journal-title":"Onco Targets Ther."},{"key":"351_CR56","doi-asserted-by":"crossref","unstructured":"Al-Ali HK, Stalbovskaya V, Gopalakrishna P, et al. Ruxolitinib overcomes the adverse prognostic effect of anemia in patients with myelofibrosis (MF) [abstract] In: 56th American Society of Hematology Annual Meeting and Exposition. 2014.","DOI":"10.1182\/blood.V124.21.4583.4583"},{"issue":"1","key":"351_CR57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2014","unstructured":"Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1):225\u20137.","journal-title":"Leukemia."},{"issue":"3","key":"351_CR58","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","volume":"70","author":"LX Tong","year":"2014","unstructured":"Tong LX, Jackson J, Kerstetter J, et al. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol. 2014;70(3):e59\u201360.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"351_CR59","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","volume":"143","author":"NG Wysham","year":"2013","unstructured":"Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1, 2 inhibitor. Chest. 2013;143(5):1478\u20139.","journal-title":"Chest."},{"issue":"7","key":"351_CR60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"RA Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7):681\u20133.","journal-title":"N Engl J Med."},{"issue":"12","key":"351_CR61","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188\u201391.","journal-title":"Mayo Clin Proc."},{"issue":"17","key":"351_CR62","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635\u201342.","journal-title":"Blood."},{"issue":"4","key":"351_CR63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/21678707.2014.888346","volume":"2","author":"CN Harrison","year":"2014","unstructured":"Harrison CN, Bennett M. Orphan drugs for myelofibrosis. Expert Opin Orphan Drugs. 2014;2(4):391\u2013405.","journal-title":"Expert Opin Orphan Drugs."},{"issue":"12","key":"351_CR64","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/jclinpath-2012-201056","volume":"65","author":"MR Qureshi","year":"2012","unstructured":"Qureshi MR, MacLean C, McMullin MF, et al. Management of myelofibrosis: a survey of current practice in the United Kingdom. J Clin Pathol. 2012;65(12):1124\u20137.","journal-title":"J Clin Pathol."},{"issue":"3","key":"351_CR65","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1038\/bcj.2012.3","volume":"2","author":"K Ballen","year":"2012","unstructured":"Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J. 2012;2(3):e59.","journal-title":"Blood Cancer J."},{"issue":"2","key":"351_CR66","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.beha.2014.07.009","volume":"27","author":"J Mascarenhas","year":"2014","unstructured":"Mascarenhas J. Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol. 2014;27(2):197\u2013208.","journal-title":"Best Pract Res Clin Haematol."},{"issue":"8","key":"351_CR67","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/leu.2014.86","volume":"28","author":"T Stubig","year":"2014","unstructured":"Stubig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis. Leukemia. 2014;28(8):1736\u20138.","journal-title":"Leukemia."},{"issue":"2","key":"351_CR68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","volume":"49","author":"N Jaekel","year":"2014","unstructured":"Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179\u201384.","journal-title":"Bone Marrow Transplant."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0351-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0351-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0351-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T02:52:01Z","timestamp":1598669521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0351-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,20]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0351-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,20]]}}}